EPAWAY
Live / Registered — Registered (as of 10 Jan 2023)
What this means for you
Registered since 10 Jan 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97003561
- Registration number
- 6946138
- Mark type
- Stylized text
- Filed
- 31 Aug 2021
- Published for opposition
- 25 Oct 2022
- Registered
- 10 Jan 2023
- Attorney of record
- Scott D. Woldow
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations for the treatment of respiratory conditions, namely, antibody for the treatment of Acute Respiratory Distress syndrome (ARDS), antibody for the treatment of Idiopathic Pulmonary Fibrosis (IPF), and Interstitial Lung Diseases (ILD); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, (HAE)
Owner
- CSL Behring GmbH, Marburg, DE
- CSL Behring GmbH, Marburg, DE
- CSL Behring GmbH, Marburg, DE
Prosecution history
- 10 Jan 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 10 Jan 2023 — REGISTERED-PRINCIPAL REGISTER
- 25 Oct 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Oct 2022 — PUBLISHED FOR OPPOSITION
- 05 Oct 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Sept 2022 — ELECTRONIC RECORD REVIEW COMPLETE
- 16 Sept 2022 — ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
- 15 Sept 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 10 Sept 2022 — EXAMINER'S AMENDMENT ENTERED
- 10 Sept 2022 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 10 Sept 2022 — EXAMINERS AMENDMENT E-MAILED
- 10 Sept 2022 — EXAMINERS AMENDMENT -WRITTEN
- 16 Aug 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 16 Aug 2022 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 16 Aug 2022 — TEAS RESPONSE TO OFFICE ACTION RECEIVED